BioScrip Inc. (NASDAQ:BIOS) shares fell 2.6% during trading on Monday . The company traded as low as $2.55 and last traded at $2.62, with a volume of 295,291 shares changing hands. The stock had previously closed at $2.69.

Separately, Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Monday.

The stock has a 50-day moving average price of $2.62 and a 200 day moving average price of $2.21. The stock’s market cap is $181.58 million.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, May 5th. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.05. The business had revenue of $238.50 million for the quarter, compared to the consensus estimate of $232.38 million. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. BioScrip’s revenue was down 2.4% compared to the same quarter last year. On average, analysts forecast that BioScrip Inc. will post ($0.20) earnings per share for the current year.

In related news, Director Coliseum Capital Management, L bought 4,200,000 shares of the firm’s stock in a transaction on Wednesday, June 22nd. The shares were bought at an average price of $2.00 per share, with a total value of $8,400,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David W. Golding bought 12,500 shares of the firm’s stock in a transaction on Friday, June 17th. The stock was bought at an average cost of $2.48 per share, for a total transaction of $31,000.00. Following the transaction, the director now directly owns 42,500 shares of the company’s stock, valued at $105,400. The disclosure for this purchase can be found here.

A number of hedge funds and institutional investors recently bought and sold shares of the stock. Gamco Investors INC. ET AL boosted its position in BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock worth $1,513,000 after buying an additional 12,250 shares during the last quarter. Diamond Hill Capital Management Inc. boosted its position in BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock worth $5,347,000 after buying an additional 74,757 shares during the last quarter. Finally, Gabelli Funds LLC boosted its position in BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock worth $20,004,000 after buying an additional 2,132,060 shares during the last quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.